• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Protara Therapeutics Inc.

    11/14/24 1:00:40 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TARA alert in real time by email
    SC 13G 1 p24-3058sc13g.htm PROTARA THERAPEUTICS, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.)*
     

    Protara Therapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    74365U107

    (CUSIP Number)
     

    September 30, 2024

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 6 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 74365U10713GPage 2 of 6 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Woodline Partners LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    1,576,567 shares of Common Stock (including 725,000 shares of Common Stock issuable upon exercise of warrants)

    6

    SHARED VOTING POWER

    - 0 -

    7

    SOLE DISPOSITIVE POWER

    1,576,567 shares of Common Stock (including 725,000 shares of Common Stock issuable upon exercise of warrants)

    8

    SHARED DISPOSITIVE POWER

    - 0 -

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,576,567 shares of Common Stock (including 725,000 shares of Common Stock issuable upon exercise of warrants)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.4%

    12

    TYPE OF REPORTING PERSON

    IA

             

     

     

    CUSIP No. 74365U10713GPage 3 of 6 Pages

     

    Item 1(a). NAME OF ISSUER.
       
      The name of the issuer is Protara Therapeutics, Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 345 Park Avenue South, 3rd Floor, New York, NY 10010.

     

    Item 2(a) NAME OF PERSON FILING:
       
      This statement is filed by Woodline Partners LP ("Woodline Partners" or the "Reporting Person"), a Delaware limited partnership, and the investment adviser to Woodline Master Fund LP (the "Woodline Fund"), with respect to the shares of Common Stock (as defined in Item 2(d) below) and shares of Common Stock underlying warrants directly held by the Woodline Fund.
       
      The filing of this statement should not be construed as an admission that the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of Woodline Partners is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111.

     

    Item 2(c). CITIZENSHIP:
       
      Woodline Partners is a Delaware limited partnership.  

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common stock, par value $0.001 per share (the "Common Stock").

     

    Item 2(e). CUSIP NUMBER:
       
      74365U107

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

     

    CUSIP No. 74365U10713GPage 4 of 6 Pages

     

      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) ¨

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
      specify the type of institution:  __________________________

     

    Item 4. OWNERSHIP.
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for the Reporting Person and is incorporated herein by reference.
       
      The percentage set forth herein is calculated based upon 20,629,772 shares of Common Stock outstanding as of August 1, 2024 as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 6, 2024, and assumes the exercise of the warrants reported herein.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: o

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2. The Woodline Fund has right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

     

    CUSIP No. 74365U10713GPage 5 of 6 Pages

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.
       
      The Reporting Person hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No. 74365U10713GPage 6 of 6 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATED: November 14, 2024

     

    WOODLINE PARTNERS LP
         
         
    By: /s/ Erin Mullen  
    Name: Erin Mullen  
    Title: General Counsel & Chief Compliance Officer  
         

     

    Get the next $TARA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TARA

    DatePrice TargetRatingAnalyst
    4/16/2025$12.00Sector Outperform
    Scotiabank
    3/14/2025Overweight
    Cantor Fitzgerald
    7/10/2023$22.00Buy
    Guggenheim
    11/8/2021$32.00 → $34.00Outperform
    Oppenheimer
    More analyst ratings

    $TARA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

      NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of William "Bill" Conkling as Chief Commercial Officer. He brings more than two decades of experience developing and commercializing novel cancer and rare disease therapeutics to Protara. "It is a pleasure to welcome Bill, a deeply experienced and proven commercial leader," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. "With an impressive track record building commercial organizations and successfully launching oncology and rare disease prod

      6/2/25 4:04:01 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protara Therapeutics to Participate in Upcoming Investor Conferences

      NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences: H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference. A fireside chat will take place on Tuesday, May 20, 2025 at 12:30 pm ET in New York.TD Cowen 6th Annual Oncology Innovation Summit. A fireside chat will take place virtually on Tuesday, May 27, 2025 at 1:30 pm ET. A live webcast of the events can be accessed by visiting the Events and Presentations section of the Company's website: https://ir.prota

      5/13/25 8:00:00 AM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

      Reported positive interim results demonstrating durable responses in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 in NMIBC Results from planned interim analysis of approximately 25 six-month evaluable BCG-Unresponsive patients expected by the end of 2025 Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support expected in Q3 2025Strengthened leadership team with key appointments of Leonardo Viana Nicacio, M.D., as Chief Medical Officer, and Shane Williams, Ph.D., as VP, Head of Human Resources, Chief People Officer Cash, cash equivalents and investments of $158 million as of March 31, 2025, expected to support planned

      5/8/25 8:00:00 AM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on Protara Therapeutics with a new price target

      Scotiabank initiated coverage of Protara Therapeutics with a rating of Sector Outperform and set a new price target of $12.00

      4/16/25 8:13:38 AM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Protara Therapeutics

      Cantor Fitzgerald initiated coverage of Protara Therapeutics with a rating of Overweight

      3/14/25 7:42:48 AM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim resumed coverage on Protara Therapeutics with a new price target

      Guggenheim resumed coverage of Protara Therapeutics with a rating of Buy and set a new price target of $22.00

      7/10/23 7:28:47 AM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Levy Richard S bought $63,800 worth of shares (20,000 units at $3.19), increasing direct ownership by 65% to 51,000 units (SEC Form 4)

      4/A - Protara Therapeutics, Inc. (0001359931) (Issuer)

      5/19/25 4:10:10 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Levy Richard S bought $63,800 worth of shares (20,000 units at $3.19), increasing direct ownership by 65% to 51,000 units (SEC Form 4)

      4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

      5/16/25 4:05:07 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARA
    SEC Filings

    See more
    • Protara Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Protara Therapeutics, Inc. (0001359931) (Filer)

      6/12/25 4:17:51 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Protara Therapeutics Inc.

      SCHEDULE 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)

      5/14/25 12:13:54 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Protara Therapeutics Inc.

      SCHEDULE 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)

      5/12/25 9:01:36 AM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARA
    Leadership Updates

    Live Leadership Updates

    See more
    • Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

      NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of William "Bill" Conkling as Chief Commercial Officer. He brings more than two decades of experience developing and commercializing novel cancer and rare disease therapeutics to Protara. "It is a pleasure to welcome Bill, a deeply experienced and proven commercial leader," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. "With an impressive track record building commercial organizations and successfully launching oncology and rare disease prod

      6/2/25 4:04:01 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

      NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer. Dr. Nicacio brings to Protara nearly 20 years of broad oncology, drug development, regulatory and commercial experience across leading biopharmaceutical and health technology companies. "We are delighted to welcome Dr. Nicacio to the Protara team," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. "As a proven leader with deep expertise spanning all stages of drug development, his guida

      4/15/25 4:13:42 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview

      - Phase 1 Study of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer Under Way - - Strong Cash Position of $130.7M as of December 31, 2021 Expected to Fund Operations into Mid-2024 - NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the fourth quarter and year ended December 31, 2021 and provided a business update. "Following a productive 2021, we are well poised to advance our pipeline in 2022, in particular, we are excited to have commenced our Phase 1 study of TARA-002 in non-muscle invasive b

      3/9/22 7:30:00 AM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Sargen Gregory

      4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

      6/13/25 4:05:27 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Levy Richard S

      4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

      6/13/25 4:05:20 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Flannelly Barry P

      4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

      6/13/25 4:05:10 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARA
    Financials

    Live finance-specific insights

    See more
    • Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

      TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patientsTARA-002 demonstrates 76% complete response rate at any time and 43% 12-month landmark complete response rate in BCG-Naïve patientsFavorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse eventsOn track to present updated interim data from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025Company to host conference call and webcast on Monday, April 28, 2025, at 8:30 a.m. ET NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company

      4/26/25 10:00:00 AM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

      NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Monday, April 28, 2025, to review updated safety and efficacy data from the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC), including data from patients who have reached the 12-month evaluation timepoint. The data will be featured during an interactive poster session at the American Urological Association 2025 Annual Meeting on Saturday, April 26, 2

      4/23/25 8:00:00 AM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

      TARA-002 demonstrates 72% six-month landmark complete response rate and 70% complete response rate at any time across BCG exposures100% six-month landmark complete response rate and 80% complete response rate at any time observed in BCG-Unresponsive patients64% six-month landmark complete response rate and 67% complete response rate at any time observed in BCG-Naïve patients80% reinduction salvage rate and compelling durability observed with 100% of patients maintaining a complete response from three months to six months across BCG exposuresFavorable safety and tolerability profile with no Grade 2 or greater treatment-related adverse eventsCompany to host conference call and webcast today at

      12/5/24 7:00:00 AM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Protara Therapeutics Inc.

      SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)

      12/17/24 4:02:03 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Protara Therapeutics Inc.

      SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)

      11/18/24 6:01:42 AM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Protara Therapeutics Inc.

      SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)

      11/14/24 1:00:40 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care